| 1 |
Ravindranath A. Chronic Hepatitis B Management in Children. Annals of Pediatric Gastroenterology & Hepatology 2022;1:7-11. [DOI: 10.5005/jp-journals-11009-0033] [Reference Citation Analysis]
|
| 2 |
Odenwald MA, Paul S. Viral hepatitis: Past, present, and future. World J Gastroenterol 2022; 28(14): 1405-1429 [DOI: 10.3748/wjg.v28.i14.1405] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 3 |
Liu C, Shih YF, Liu CJ. Immunopathogenesis of Acute Flare of Chronic Hepatitis B: With Emphasis on the Role of Cytokines and Chemokines. Int J Mol Sci 2022;23:1407. [PMID: 35163330 DOI: 10.3390/ijms23031407] [Reference Citation Analysis]
|
| 4 |
Song DS, Jang JW, Yoo SH, Kwon JH, Nam SW, Bae SH, Choi JY, Yoon SK. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B. Clin Infect Dis 2021;73:e892-903. [PMID: 33417679 DOI: 10.1093/cid/ciab007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Na JH, Kim JH, Choe WH, Kwon SY, Yoo BC. Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients. Korean J Gastroenterol 2021;77:285-93. [PMID: 34158448 DOI: 10.4166/kjg.2021.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Li T, Liang Y, Zhang M, Liu F, Zhang L, Yang B, Wang L. Nucleoside/nucleotide analog consolidation therapy in hepatitis B e-antigen positive chronic hepatitis B patients: Three years should be preferred. Hepatol Res 2021;51:633-40. [PMID: 33772988 DOI: 10.1111/hepr.13641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 7 |
Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 8 |
Zeng YL, Qin L, Wei WJ, Cai H, Yu XF, Zhang W, Wu XL, Liu XB, Chen WM, You P, Hong MZ, Liu Y, Dong X, Shia BC, Niu JJ, Pan JS. Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy. Sci Rep 2021;11:3253. [PMID: 33547384 DOI: 10.1038/s41598-021-82939-1] [Reference Citation Analysis]
|
| 9 |
Hu C, Song Y, Tang C, Li M, Liu J, Liu J, Liao M, Zhou F, Zhang YY, Zhou Y. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience. Clin Ther 2021;43:572-581.e3. [PMID: 33516527 DOI: 10.1016/j.clinthera.2020.12.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 11 |
Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
|
| 12 |
Wen S, Tsai C, Cheng L, Huang C, Kuo W. Predictors of HBeAg loss after nucleos(t)ide analogues treatment for chronic hepatitis B: A preliminary finding. Adv in Digestive Med 2021;8:10-8. [DOI: 10.1002/aid2.13190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 13 |
Wang CH, Chang KK, Lin RC, Kuo MJ, Yang CC, Tseng YT. Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study. Medicine (Baltimore) 2020;99:e19907. [PMID: 32358357 DOI: 10.1097/MD.0000000000019907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 14 |
Lee HW, Lee JI, Kim S, Kim S, Chang HY, Lee KS. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance. BMC Gastroenterol 2020;20:113. [PMID: 32305059 DOI: 10.1186/s12876-020-01236-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 15 |
Wübbolding M, Cornberg M, Höner zu Siederdissen C. Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV. Curr Hepatology Rep 2019;18:512-21. [DOI: 10.1007/s11901-019-00502-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 16 |
Abdurakhmanov D, Ibragimov E, Rozina T, Nikulkina E, Mazurchik N. HBsAg levels as a guide for finite treatment duration of chronic hepatitis B. Clin Res Hepatol Gastroenterol 2019;43:e73-5. [PMID: 30670355 DOI: 10.1016/j.clinre.2018.12.007] [Reference Citation Analysis]
|
| 17 |
Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 124] [Article Influence: 28.3] [Reference Citation Analysis]
|
| 18 |
Perez-alamino R. Hepatitis Arthritis: HBV and HCV. Infections and the Rheumatic Diseases 2019. [DOI: 10.1007/978-3-030-23311-2_10] [Reference Citation Analysis]
|
| 19 |
Liu F, Liu ZR, Li T, Liu Y, Zhang M, Xue Y, Zhang LX, Ye Q, Fan XP, Wang L. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. J Dig Dis 2018;19:561-71. [PMID: 30098114 DOI: 10.1111/1751-2980.12654] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 20 |
Xu WX, Zhang Q, Zhu X, Lin CS, Chen YM, Deng H, Mei YY, Zhao ZX, Xie DY, Gao ZL, Xie C, Peng L. 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse. Can J Gastroenterol Hepatol 2018;2018:1817680. [PMID: 29862225 DOI: 10.1155/2018/1817680] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 21 |
Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, Jiang J, Xie Q, Dou X, Sun Y, Li Y, Liu Y, Liu G, Mao D, Chi X, Tang H, Li X, Xie Y, Chen X, Jiang J, Zhao P, Hou J, Gao Z, Fan H, Ding J, Zhang D, Ren H. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol 2018;6:25-34. [PMID: 29577029 DOI: 10.14218/JCTH.2017.00072] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 22 |
Arora A, Singh SP, Kumar A, Saraswat VA, Aggarwal R, Bangar M, Bhaumik P, Devarbhavi H, Dhiman RK, Dixit VK, Goel A, Goswami B, Kapoor D, Madan K, Narayan J, Nijhawan S, Pandey G, Rai RR, Sahu MK, Saraf N, Shalimar, Shenoy T, Thomas V, Wadhawan M; INASL Hepatitis B Taskforce. INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements. J Clin Exp Hepatol 2018;8:58-80. [PMID: 29743798 DOI: 10.1016/j.jceh.2017.12.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 23 |
Li T, Liu F, Zhang L, Ye Q, Fan X, Xue Y, Wang L. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs. Saudi J Gastroenterol 2018;24:30-6. [PMID: 29451182 DOI: 10.4103/sjg.SJG_228_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 24 |
Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, Chuang WL, Tabak F, Mehta R, Petersen J, Guyer W, Jump B, Chan A, Subramanian M, Crans G, Fung S, Buti M, Gaeta GB, Hui AJ, Papatheodoridis G, Flisiak R, Chan HLY. Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis. Dig Dis Sci 2018;63:3487-97. [PMID: 30136045 DOI: 10.1007/s10620-018-5251-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 25 |
Xu Y, Liu Y, Zhao M, Chen Y, Xie C, Gong M, Deng H, Li X, Sun J, Hou J, Wu H, Wang Z. Dynamic Perturbations of CD4 and CD8 T Cell Receptor Repertoires in Chronic Hepatitis B Patients upon Oral Antiviral Therapy. Front Immunol 2017;8:1142. [PMID: 28959264 DOI: 10.3389/fimmu.2017.01142] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 26 |
Liu Z, Liu F, Wang L, Liu Y, Zhang M, Li T. Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study. Hepatol Res 2017;47:1000-7. [PMID: 27917568 DOI: 10.1111/hepr.12836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 27 |
Shaaban Hanafy A. Impact of hepatitis B vaccination on HBsAg kinetics, interferon-inducible protein 10 level and recurrence of viremia. Cytokine 2017;99:99-105. [PMID: 28802168 DOI: 10.1016/j.cyto.2017.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 28 |
Chi H, Hansen BE, Guo S, Zhang NP, Qi X, Chen L, Guo Q, Arends P, Wang JY, Verhey E, de Knegt RJ, Xie Q, Janssen HLA. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON). J Infect Dis 2017;215:1085-93. [PMID: 28329061 DOI: 10.1093/infdis/jix024] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 29 |
Lim L, Thompson A, Patterson S, George J, Strasser S, Lee A, Sievert W, Nicoll A, Desmond P, Roberts S, Marion K, Bowden S, Locarnini S, Angus P. Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy. Liver Int 2017;37:827-35. [PMID: 27896895 DOI: 10.1111/liv.13331] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 30 |
Cao J, Chi H, Yu T, Li Z, Hansen BE, Zhang X, Zhong C, Sun J, Hou J, Janssen HLA. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study. J Infect Dis. 2017;215:581-589. [PMID: 28329347 DOI: 10.1093/infdis/jix025] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 31 |
Kim DH, Choi JW, Seo JH, Cho YS, Won SY, Park BK, Jeon HH, Shin SY, Lee CK. Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA. Yonsei Med J 2017;58:552-6. [PMID: 28332360 DOI: 10.3349/ymj.2017.58.3.552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 32 |
Chong CH, Lim SG. When can we stop nucleoside analogues in patients with chronic hepatitis B? Liver Int 2017;37 Suppl 1:52-8. [PMID: 28052620 DOI: 10.1111/liv.13314] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 33 |
Kang SH, Kang K, Jong Eun Y, Lee YS, Kim TS, Yoo YJ, Suh SJ, Yoon EL, Jung YK, Kim JH, Seo YS, Yim HJ, Byun KS. Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study. J Med Virol 2017;89:849-56. [PMID: 27769101 DOI: 10.1002/jmv.24715] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 34 |
Park CH, Kim HY, Lee SW, Song do S, Song MJ, Kwon JH, You CR, Jang JW, Kim CW, Choi SW, Bae SH, Choi JY, Yoon SK. On-treatment and off-treatment efficacy of entecavir in a real-life cohort of chronic hepatitis B patients. Eur J Gastroenterol Hepatol 2016;28:1179-87. [PMID: 27428552 DOI: 10.1097/MEG.0000000000000691] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 35 |
Lee HA, Seo YS, Park SW, Park SJ, Kim TH, Suh SJ, Jung YK, Kim JH, An H, Yim HJ, Yeon JE, Byun KS, Um SH. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. Clin Mol Hepatol. 2016;22:382-389. [PMID: 27729633 DOI: 10.3350/cmh.2016.0047] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 36 |
Jung KS, Park JY, Chon YE, Kim HS, Kang W, Kim BK, Kim SU, Kim do Y, Han KH, Ahn SH. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol 2016;51:830-9. [PMID: 26687058 DOI: 10.1007/s00535-015-1153-1] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 37 |
An J, Shim JH, Kim SO, Choi J, Kim SW, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis. J Med Virol. 2016;88:1576-1586. [PMID: 26945543 DOI: 10.1002/jmv.24512] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 38 |
Zhang L, Zhang M, Li H, Chen Z, Luo A, Liu B, Chen M, Peng M, Ren H, Hu P. Tfh cell-mediated humoral immune response and HBsAg level can predict HBeAg seroconversion in chronic hepatitis B patients receiving peginterferon-α therapy. Mol Immunol 2016;73:37-45. [PMID: 27037894 DOI: 10.1016/j.molimm.2016.03.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 39 |
Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 125] [Cited by in F6Publishing: 144] [Article Influence: 17.9] [Reference Citation Analysis]
|
| 40 |
Nagata N, Kagawa T, Hirose S, Arase Y, Tsuruya K, Anzai K, Shiraishi K, Mine T. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. BMC Gastroenterol 2016;16:38. [PMID: 26987437 DOI: 10.1186/s12876-016-0454-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 41 |
Wong DJ, Locarnini SA, Thompson AJ. Hepatitis B Virus. Clinical Virology 2016. [DOI: 10.1128/9781555819439.ch32] [Reference Citation Analysis]
|
| 42 |
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1348] [Cited by in F6Publishing: 1457] [Article Influence: 168.5] [Reference Citation Analysis]
|
| 43 |
Lu J, Li J, Liu Y, Ren S, Cao Z, Jin Y, Ma L, Shen C, Chen X. Study on Post-Treatment Relapse in HBeAg Positive CHB Patients. PLoS One 2015;10:e0141072. [PMID: 26524467 DOI: 10.1371/journal.pone.0141072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 44 |
Fong TL, Tien A, Jo KJ, Chu D, Cheung E, Mena EA, Phan QQ, Yu AS, Mohammed W, Velasco A, LeDuc VH, Nguyen N, Han SB, Chang M, Bae HS, Cho YW, Tong MJ, Cooper SL. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Dig Dis Sci 2015;60:3465-72. [PMID: 26138653 DOI: 10.1007/s10620-015-3775-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 45 |
Chen L, Gan QR, Zhang DQ, Yao LF, Lin RS, Li Q, Lin MH, Yu DM, Zhang XX, Pan C. Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic hepatitis B patients. Clin Microbiol Infect 2016;22:201-7. [PMID: 26493847 DOI: 10.1016/j.cmi.2015.10.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 46 |
Siakavellas SI, Papatheodoridis GV. Controversial Issues in Current Treatment of Chronic HBV Infection. Curr Hepatology Rep 2015;14:164-170. [DOI: 10.1007/s11901-015-0268-4] [Reference Citation Analysis]
|
| 47 |
Lee HW, Kwon JC, Oh IS, Chang HY, Cha YJ, Choi IS, Kim HJ. Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response. Antimicrob Agents Chemother 2015;59:5348-56. [PMID: 26100697 DOI: 10.1128/AAC.01017-15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 48 |
Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, Streinu-Cercel A, Wang JY, Idilman R, Reesink HW, Diculescu M, Simon K, Voiculescu M, Akdogan M, Mazur W, Reijnders JG, Verhey E, Hansen BE, Janssen HL; ARES Study Group. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology 2015;61:1512-22. [PMID: 25348661 DOI: 10.1002/hep.27586] [Cited by in Crossref: 133] [Cited by in F6Publishing: 140] [Article Influence: 16.6] [Reference Citation Analysis]
|
| 49 |
Chi H, Hansen BE, Yim C, Arends P, Abu-Amara M, van der Eijk AA, Feld JJ, de Knegt RJ, Wong DK, Janssen HL. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther 2015;41:867-76. [PMID: 25752878 DOI: 10.1111/apt.13150] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 10.1] [Reference Citation Analysis]
|
| 50 |
Yao CC, Lee CM, Hung CH, Wang JH, Hu TH, Lu SN, Changchien CS, Hsu MC, Chen CH. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion. J Gastroenterol Hepatol 2015;30:918-24. [PMID: 25532588 DOI: 10.1111/jgh.12874] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 51 |
Nard FD, Todoerti M, Grosso V, Monti S, Breda S, Rossi S, Montecucco C, Caporali R. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World J Hepatol 2015;7:344-61. [PMID: 25848463 DOI: 10.4254/wjh.v7.i3.344] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 6.9] [Reference Citation Analysis]
|
| 52 |
Dienstag JL, Delemos AS. Viral Hepatitis. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases 2015. [DOI: 10.1016/b978-1-4557-4801-3.00119-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 53 |
Chang ML, Liaw YF. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatol 2014;61:1407-17. [PMID: 25178562 DOI: 10.1016/j.jhep.2014.08.033] [Cited by in Crossref: 201] [Cited by in F6Publishing: 210] [Article Influence: 22.3] [Reference Citation Analysis]
|
| 54 |
Kuo LF, Lee CM, Hung CH, Wang JH, Hu TH, Lu SN, Changchien CS, Chen CH. High risk of hepatitis B virus reactivation in nucleos(t)ide analogue-induced hepatitis B e antigen seroconverters older than 40 years. Dig Dis Sci 2014;59:2580-7. [PMID: 24846794 DOI: 10.1007/s10620-014-3194-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 55 |
Azmi AN, Tan SS, Mohamed R. Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. World J Gastroenterol 2014; 20(34): 12045-12055 [PMID: 25232242 DOI: 10.3748/wjg.v20.i34.12045] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 56 |
Niederau C. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014; 20(33): 11595-11617 [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 57 |
Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, Lee CM. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol 2014;61:515-22. [PMID: 24798617 DOI: 10.1016/j.jhep.2014.04.029] [Cited by in Crossref: 116] [Cited by in F6Publishing: 118] [Article Influence: 12.9] [Reference Citation Analysis]
|
| 58 |
Sohn HR, Min BY, Song JC, Seong MH, Lee SS, Jang ES, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW. Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infect Dis. 2014;14:439. [PMID: 25125320 DOI: 10.1186/1471-2334-14-439] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 59 |
Vallet-Pichard A, Pol S. Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal. Therap Adv Gastroenterol 2014;7:148-55. [PMID: 25057295 DOI: 10.1177/1756283X14524614] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 60 |
Dan YY, Wong JB, Hamid SS, Han KH, Jia JD, Liu CJ, Piratvisuth T, Lok AS, Lim SG. Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. Hepatol Int. 2014;8:382-394. [PMID: 26202640 DOI: 10.1007/s12072-014-9549-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 61 |
Kang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. World J Gastroenterol 2014; 20(23): 7207-7212 [PMID: 24966590 DOI: 10.3748/wjg.v20.i23.7207] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 62 |
Hyeong Lee C. Oral Antiviral Therapy for Chronic Hepatitis B Virus Infection: Is Continuous Treatment Needed? GHOA 2014;1. [DOI: 10.15406/ghoa.2014.01.00005] [Reference Citation Analysis]
|
| 63 |
Martín-mateos RM, Moreira Vicente VF, Téllez-villajos L, García-sánchez C, Maroto-castellanos MT, García-alonso FJ, Mateos-lindemann ML, Albillos A. Tratamiento de la hepatitis crónica B antígeno e positiva con antivirales orales: experiencia y resultados en la práctica clínica. Gastroenterología y Hepatología 2014;37:280-8. [DOI: 10.1016/j.gastrohep.2013.11.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 64 |
Lee HW, Kang W, Ahn SH, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Kim JK, Kim DY, Paik YH, Lee CK, Choi IS, Lee KS, Han KH. Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients. J Gastroenterol Hepatol 2014;29:1049-55. [PMID: 24575848 DOI: 10.1111/jgh.12522] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 65 |
Yapali S, Talaat N, Lok AS. Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol 2014;12:16-26. [PMID: 23660419 DOI: 10.1016/j.cgh.2013.04.036] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 8.4] [Reference Citation Analysis]
|
| 66 |
Abaalkhail F, Elsiesy H, AlOmair A, Alghamdi MY, Alalwan A, AlMasri N, Al-Hamoudi W; Saudi Association for the Study of Liver Diseases and Transplantation (SASLT). SASLT practice guidelines for the management of hepatitis B virus. Saudi J Gastroenterol 2014;20:5-25. [PMID: 24496154 DOI: 10.4103/1319-3767.126311] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 67 |
Peng CY, Hsieh TC, Hsieh TY, Tseng KC, Lin CL, Su TH, Tseng TC, Lin HH, Wang CC, Kao JH. HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. J Formos Med Assoc 2015;114:308-13. [PMID: 24315616 DOI: 10.1016/j.jfma.2013.10.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 68 |
Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, Kelly D, Mieli-Vergani G; European Society of Pediatric Gastroenterology, Hepatology and Nutrition. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatol 2013;59:814-29. [PMID: 23707367 DOI: 10.1016/j.jhep.2013.05.016] [Cited by in Crossref: 151] [Cited by in F6Publishing: 156] [Article Influence: 15.1] [Reference Citation Analysis]
|
| 69 |
Li Y, Ma S, Tang L, Li Y, Wang W, Huang X, Lai Q, Zhang M, Sun J, Li CK, Abbott WG, Naoumov NV, Zhang Y, Hou J. Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection. Hepatology 2013;58:1277-86. [PMID: 23703545 DOI: 10.1002/hep.26489] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 70 |
Wong GL, Chong C, Wong VW. Tertiary Prevention of HBV-related HCC in Asia. Curr Hepatitis Rep 2013;12:157-164. [DOI: 10.1007/s11901-013-0171-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 71 |
Peng C. Nucleos(t)ide Analogues Therapy for Chronic Hepatitis B in Taiwan: Short-Term Versus Long-Term. Curr Hepatitis Rep 2013;12:181-187. [DOI: 10.1007/s11901-013-0173-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 72 |
Asselah T, Marcellin P. Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B. Clin Liver Dis 2013;17:445-50. [PMID: 23905815 DOI: 10.1016/j.cld.2013.05.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 73 |
Kwon HK, Lok AS. Treatment of Hepatitis B. Viral Hepatitis 2013. [DOI: 10.1002/9781118637272.ch14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 74 |
Kwon JH, Jang JW, Choi JY, Park CH, Yoo SH, Bae SH, Yoon SK. Should lamivudine monotherapy be stopped or continued in patients infected with hepatitis B with favorable responses after more than 5 years of treatment? J Med Virol. 2013;85:34-42. [PMID: 23154874 DOI: 10.1002/jmv.23421] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 75 |
Chan WK, Tan S, Mohamed R. Stopping Therapy in HBeAg Negative Disease. Curr Hepatitis Rep 2013;12:105-11. [DOI: 10.1007/s11901-013-0167-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 76 |
Wang WH, Cao JB. Antiviral therapy for hepatitis B virus-associated hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2013; 21(5): 415-420 [DOI: 10.11569/wcjd.v21.i5.415] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 77 |
Ma H, Jia J. Why do I treat HBeAg-positive chronic hepatitis B patients with a nucleoside analogue. Liver Int 2013;33 Suppl 1:133-6. [PMID: 23286857 DOI: 10.1111/liv.12065] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 78 |
Kim HY, Choi JY, Park CH, Jang JW, Kim CW, Bae SH, Yoon SK, Yang JM, Lee CD, Lee YS. Outcome after discontinuing antiviral agents during pregnancy in women infected with hepatitis B virus. J Clin Virol 2013;56:299-305. [PMID: 23273664 DOI: 10.1016/j.jcv.2012.11.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 79 |
Tran TT. High frequency of viremia after hepatitis B e antigen seroconversion and consolidation therapy: setting realistic expectations. J Clin Gastroenterol 2012;46:807-8. [PMID: 23060214 DOI: 10.1097/MCG.0b013e31826b3030] [Reference Citation Analysis]
|
| 80 |
Jin YJ, Kim KM, Yoo DJ, Shim JH, Lee HC, Chung YH, Lee YS, Suh DJ. Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients. Virol J. 2012;9:239. [PMID: 23078793 DOI: 10.1186/1743-422x-9-239] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 81 |
Tseng T, Liu C, Su T, Yang H, Wang C, Chen C, Kuo SF, Liu C, Chen P, Chen D, Kao J. Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. Journal of Infectious Diseases 2012;206:1521-31. [DOI: 10.1093/infdis/jis569] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 82 |
Buti M, García-samaniego J, Prieto M, Rodríguez M, Sánchez-tapias JM, Suárez E, Esteban R. Documento de consenso de la AEEH sobre el tratamiento de la infección por el virus de la hepatitis B (2012). Gastroenterología y Hepatología 2012;35:512-28. [DOI: 10.1016/j.gastrohep.2012.04.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 83 |
European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85. [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010] [Cited by in Crossref: 2323] [Cited by in F6Publishing: 2515] [Article Influence: 211.2] [Reference Citation Analysis]
|
| 84 |
Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 116] [Cited by in F6Publishing: 138] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 85 |
Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 742] [Cited by in F6Publishing: 688] [Article Influence: 67.5] [Reference Citation Analysis]
|
| 86 |
Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 2012;142:1360-1368.e1. [PMID: 22537444 DOI: 10.1053/j.gastro.2012.01.044] [Cited by in Crossref: 102] [Cited by in F6Publishing: 112] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 87 |
Lok ASF, Negro F. Hepatitis B and D. Schiff's Diseases of the Liver 2011. [DOI: 10.1002/9781119950509.ch24] [Reference Citation Analysis]
|
| 88 |
Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, Xie R, Ge S, Hu J, Jiang Z, Zhu M, Wong VW, Chan HL. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther 2011;34:344-52. [PMID: 21671967 DOI: 10.1111/j.1365-2036.2011.04738.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 73] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 89 |
Kim KH, Sinn DH, Yun WK, Cho HC, Lee YY, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW. Defining virologic relapse in chronic hepatitis B. Dig Dis Sci 2011;56:2432-8. [PMID: 21318588 DOI: 10.1007/s10620-011-1597-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 90 |
Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011;8:275-84. [PMID: 21423260 DOI: 10.1038/nrgastro.2011.33] [Cited by in Crossref: 191] [Cited by in F6Publishing: 194] [Article Influence: 15.9] [Reference Citation Analysis]
|
| 91 |
Carosi G, Rizzetto M, Alberti A, Cariti G, Colombo M, Craxì A, Filice G, Levrero M, Mazzotta F, Pastore G, Piccinino F, Prati D, Raimondo G, Sagnelli E, Toti M, Brunetto M, Bruno R, Di Marco V, Ferrari C, Gaeta GB, Lampertico P, Marzano A, Pollicino T, Puoti M, Santantonio T, Smedile A. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis 2011;43:259-65. [PMID: 21276760 DOI: 10.1016/j.dld.2010.10.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 92 |
Fung J, Lai CL, Yuen MF. To stop or not to stop: the quest for long-term viral suppression. J Gastroenterol Hepatol 2011;26:420-2. [PMID: 21332537 DOI: 10.1111/j.1440-1746.2011.06604.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 93 |
Chan HL, Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol 2011;26 Suppl 1:131-7. [PMID: 21199524 DOI: 10.1111/j.1440-1746.2010.06544.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 94 |
Chotiyaputta W, Lok AS. Endpoints of hepatitis B treatment. J Viral Hepat 2010;17:675-84. [PMID: 20840331 DOI: 10.1111/j.1365-2893.2010.01369.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 95 |
Lee JM, Ahn SH. [Predictors for virologic response in management of chronic hepatitis B]. Korean J Hepatol 2010;16:1-4. [PMID: 20375637 DOI: 10.3350/kjhep.2010.16.1.1] [Reference Citation Analysis]
|
